You are here
Professor Suzanne Garland
Professor Suzanne Garland is an internationally-recognised clinical microbiologist and sexual health physician, with particular expertise in infectious diseases relating to reproductive health and infants.
After completing her Bachelor of Medicine at the University of Melbourne in 1971, she worked overseas for a year as a Research Fellow at Harvard University in Boston. She started as Director of Clinical Microbiology and Infectious Diseases at the Royal Women's Hospital in 1984. Recognised for her research on infectious diseases, particularly in women's and newborn health, Professor Garland is a regular advisor to the World Health Organisation on sexual and reproductive health infections, cervical cancer and human papillomavirus (HPV).
Professor Garland and her team were leaders in the role of patient self-collected genital sampling in the detection by molecular techniques of reproductive tract infections, eg Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and human papillomaviruses (HPV). She has been involved with HPV role in cancers, precursor lesions (CIN3), phase 3 clinical trials for HPV prophylactic vaccines and more recently, vaccine effectiveness studies. Her laboratory is the Western Pacific Regional reference laboratory of the HPV Labnet, established by the World Health Organization (WHO).
Professor Garland was integral to the establishment 10 years ago of the Asian-Oceania Research Organisation on Genital Infection and Neoplasia (AOGIN), which brings together clinicians and scientists in the region whose work is related to genital infections and neoplasia. She was the inaugural and past president of the organisation and remains an ongoing board advisor.
- Head of Clinical Microbiology and Infectious Diseases, Royal Women's Hospital
- Prof Suzanne Garland speaks about the largest international evaluation of the human papillomavirus vaccine; ‘Jabs punch cancer virus; Gardasil success shown’.
Herald Sun, Author: Brigid O'Connell, 30 June 2016.
- Prof Suzanne Garland profiled in media coverage for Women’s Day 2016; ‘Just what the Doctor ordered’ - Melbourne women who continue to be trail blazers in the areas of research, IVF, emergency care and surgery.
Herald Sun, Author: Catherine Lambert, 05 March 2016.
- Outstanding Contribution to Research in Sexual Health Medicine Award. The Royal Australasian College for Physicians: Inaugural award, Australasian Chapter of Sexual Health Medicine National meeting. October 2007, Queensland, Australia
- Study award – "Squamous cell carcinoma of the vulva: HPV detection and its correlation with p16INK and p53 overexpression." The 3rd Intercontinental Congress of Pathology, Barcelona, 17-22 May 2008. (B. Lloveras, M. Alejo, J. Ordi, A. Vidal, O. Clavero, J. Klaustermeier, N. Guimerà, M. Vergara, X. Vallès, SM. Garland, HR. Shin, J. Salmerón, E. Kasamatsu, A. Cubilla, E. Cruz, CY. Chou, E. López, G. Hernández, EJ. Domingo, A. Nessa, E. Kestler, A .Jain, V. Mandys, S. Tous, R. Font, W. Quint, N. Muñoz, S. De Sanjose, FX. Bosch)
- Best poster award – “Natural history of genital warts: analysis of the placebo arm of 2 randomised phase 3 trials of a quadrivalent HPV 6, 11, 16, 18 vaccine." International Society for the Study of Vulvovaginal Disease (ISSVD) World Congress, September 2009. (SM. Garland, M. Steben, H. Sings, M. James, R. Railkar, E. Barr, R Haupt, E. Joura for the FUTURE I and II trials study groups)
- NHMRC-funded research on “Infectious Diseases Research in Reproductive Health: Particularly of Women and Babies" was selected to appear in the 2010 edition of NHMRC's 10 of the Best Research Projects book.
- Best Poster – Assessing the effectiveness of the human papillomavirus vaccination program in Victoria, Australia, Poster No.57, Presentation Type: IUSTI Poster Theme: IUSTI – Epidemiology (Non HI), Awarded the IUSTI (International Union Against Sexually Transmitted Infections) E Young, J Brotherton, S Tabrizi, M Pitts, D Gertig, J Wark, Y Jayasinghe, SM Garland, 'Bronze Prize' for highly commended in the poster presentations, on the occasion of the 13th IUSTI World Congress, Melbourne 2012.
Professor Garland is leading research on the human papillomavirus (HPV) and its role in cervical cancer in a number of clinically-based research projects. These include an assessment of the cervical vaccine's effectiveness in the Australian population. This is another world first for Australia. Due to the high HPV vaccine coverage rate in young girls and women, it is possible to see the outcomes of vaccine effectiveness in a real world situation. This study is recruiting women of vaccine eligible age to look at the impact of the vaccine on the HPV vaccine-related genotype infections, as well as looking at disease outcomes. Interim analyses are showing significant effects. Now that Australia is also vaccinating young boys, the researchers are embarking on a vaccine effectiveness study in young men.
An additional research area is the development and application of molecular testing for detection of sexually transmitted infections (STI) of marginalised, remote populations.
Professor Garland is the Chief Investigator of the biggest case-control study internationally examining the value of probiotics in reducing late onset sepsis in very low birth weight infants (PROPREMs study). The outcome of this study has influenced neonatal care locally and globally as it showed definitively a significant reduction for necrotising enterocolitis.
Meanwhile, the Young Female Health Initiative (YFHI) is an exciting and ambitious new project recruiting Victorian women aged 16 to 25 years using social media. Detailed questionnaires evaluate their lifestyle, behaviour and physical and mental health. This study will provide important new insights into the health patterns of young women today, and will enable the development of education and intervention tools and health policies to improve health and wellbeing throughout their lives.
- Young Female Health Initiatives (YFHI)-v SAFE-D
- ProPrems - Allergy in Premature Infants
- VACCINE – The Vaccine Against Cervical Cancer Impact and Effectiveness study
- Understanding why some young women do not accept the HPV Vaccine
- ProPrems - Effect of probiotic supplementation on long term colonisation of probiotic strains in preterm infant